
TY  - JOUR
TI  - Abstracts
JO  - Basic & Clinical Pharmacology & Toxicology
JA  - Basic Clin Pharmacol Toxicol
VL  - 125
IS  - S2
SN  - 1742-7835
UR  - https://doi.org/10.1111/bcpt.13297
DO  - doi:10.1111/bcpt.13297
SP  - 3
EP  - 330
PY  - 2019
ER  - 

C7  - pp. 545-579
TI  - Index
SN  - 9780470066409
UR  - https://doi.org/10.1002/9780470516157.index02
DO  - doi:10.1002/9780470516157.index02
SP  - 545-579
PY  - 2019
ER  - 

C7  - pp. 545-579
TI  - Index
SN  - 9780470066386
UR  - https://doi.org/10.1002/9780470772973.index
DO  - doi:10.1002/9780470772973.index
SP  - 545-579
PY  - 2019
ER  - 

TY  - JOUR
TI  - POSTER SESSION: CLINICAL
JO  - European Journal of Heart Failure
JA  - European Journal of Heart Failure
VL  - 12
IS  - S1
SN  - 9780470066386
UR  - https://doi.org/10.1093/eurjhf/hst009
DO  - doi:10.1093/eurjhf/hst009
SP  - S73
EP  - S325
PY  - 2013
ER  - 

TY  - JOUR
TI  - ACCP Annual Meeting-Abstracts and index of authors
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
VL  - 11
IS  - 3
SN  - 9780470066386
UR  - https://doi.org/10.1002/j.1875-9114.1991.tb02638.x
DO  - doi:10.1002/j.1875-9114.1991.tb02638.x
SP  - 264
EP  - 290
PY  - 1991
ER  - 

TY  - JOUR
TI  - Abstracts and Index of Authors
JO  - Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
JA  - Pharmacotherapy
VL  - 33
IS  - 10
SN  - 9780470066386
UR  - https://doi.org/10.1002/phar.1356
DO  - doi:10.1002/phar.1356
SP  - e182
EP  - e332
PY  - 2013
ER  - 

TY  - JOUR
TI  - Index
JO  - FEBS Letters
VL  - 298
IS  - S1
SN  - 9780470066386
UR  - https://doi.org/10.1016/0014-5793(92)80006-3
DO  - doi:10.1016/0014-5793(92)80006-3
SP  - 1
EP  - 202
PY  - 1992
ER  - 

TY  - JOUR
TI  - Mini Orals
JO  - Nephrology
JA  - Nephrology
VL  - 22
IS  - S3
SN  - 9780470066386
UR  - https://doi.org/10.1111/nep.13104
DO  - doi:10.1111/nep.13104
SP  - 18
EP  - 50
PY  - 2017
ER  - 

TY  - JOUR
C7  - e27713
TI  - 2019 ASPHO ABSTRACTS
JO  - Pediatric Blood & Cancer
JA  - Pediatr Blood Cancer
VL  - 66
IS  - S2
SN  - 9780470066386
UR  - https://doi.org/10.1002/pbc.27713
DO  - doi:10.1002/pbc.27713
SP  - e27713
PY  - 2019
ER  - 

TY  - JOUR
TI  - Paper Abstract
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 65
IS  - S1
SN  - 9780470066386
UR  - https://doi.org/10.1111/jgs.14915
DO  - doi:10.1111/jgs.14915
SP  - S1
EP  - S289
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Neurourology and Urodynamics
JA  - Neurourology and Urodynamics
VL  - 37
IS  - S1
SN  - 9780470066386
UR  - https://doi.org/10.1002/nau.23524
DO  - doi:10.1002/nau.23524
SP  - S518
EP  - S699
PY  - 2018
ER  - 

TY  - JOUR
TI  - Oral Abstract
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 16
IS  - S3
SN  - 9780470066386
UR  - https://doi.org/10.1111/ajt.13897
DO  - doi:10.1111/ajt.13897
SP  - 203
EP  - 404
PY  - 2016
ER  - 

TY  - JOUR
AU  - Park, Soon Ho
AU  - Seo, Yiel-Hea
AU  - Park, Pil-Whan
AU  - Kim, Kyung-Hee
AU  - Seo, Ja Young
AU  - Lee, Hwan Tae
AU  - Kwoun, Woo-Jae
AU  - Ahn, Jeong-Yeal
C7  - e22869
TI  - Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution
JO  - Journal of Clinical Laboratory Analysis
JA  - J Clin Lab Anal
VL  - 33
IS  - 5
SN  - 9780470066386
UR  - https://doi.org/10.1002/jcla.22869
DO  - doi:10.1002/jcla.22869
SP  - e22869
KW  - anti-factor Xa activity
KW  - antithrombin
KW  - apixaban
KW  - dilute Russell viper venom time
KW  - prothrombin time
KW  - rivaroxaban
PY  - 2019
AB  - Background Apixaban and rivaroxaban are approved for the prevention and treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and embolic stroke in atrial fibrillation (AF) patients. The aim of this study was to find appropriate methods of monitoring the anticoagulant effects of are direct oral anticoagulants (DOACs) and establish on-therapy ranges using conventional tests. Methods A total of 184 samples were collected from 91 patients receiving DOACs. Concentrations of apixaban and rivaroxaban in plasma were accessed by an anti-factor Xa chromogenic assay. PT, APTT, antithrombin, D-dimer, dRVVT screen/confirm, FDP, and fibrinogen levels were measured. On-therapy ranges were calculated by substituting previously reported trough plasma concentrations of DOACs. Results Anti-factor Xa chromogenic assay-based DOACs levels were 26.0-279.5 (115.9 ± 56.5) ng/mL for apixaban at 2.5 mg BID, 19.9-565.1 (205.3 ± 162.4) ng/mL for apixaban at 5 mg BID, 2.3-395.3 (205.3 ± 162.4) ng/mL for rivaroxaban at 15 mg OD, 3.6-494.8 (119.6 ± 95.1) ng/mL for rivaroxaban at 20 mg OD, and 9.6-431.4 (140.8 ± 113.6) ng/mL for rivaroxaban at 15 mg BID. PT (%), antithrombin, and dRVVT confirm tests showed good correlation with plasma apixaban levels. Plasma rivaroxaban concentrations were correlated well with PT (sec), PT (%),and dRVVT confirm results. On-therapy ranges established for dRVVT confirm test by linear regression were as follows: 1.32-1.52 for apixaban 2.5 mg BID, 1.12-1.75 for apixaban 5 mg BID, 1.11-1.78 for rivaroxaban 15 mg OD, 1.09-1.64 for rivaroxaban 20 mg OD, and 1.22-1.81 for rivaroxaban 20 mg BID. Conclusions Apixaban concentrations were well correlated with PT (%), antithrombin, and dRVVT confirm test. Rivaroxaban concentrations showed good correlation with PT (sec), PT (%), and dRVVT confirm test.
ER  - 

TY  - JOUR
TI  - Poster Sessions: Basic
JO  - American Journal of Transplantation
VL  - 14
IS  - S3
SN  - 9780470066386
UR  - https://doi.org/10.1111/ajt.12888
DO  - doi:10.1111/ajt.12888
SP  - 278
EP  - 419
PY  - 2014
ER  - 

TY  - JOUR
AU  - McKinlay, J.
AU  - Tyson, E.
AU  - Forni, L. G.
TI  - Renal complications of anaesthesia
JO  - Anaesthesia
JA  - Anaesthesia
VL  - 73
IS  - S1
SN  - 9780470066386
UR  - https://doi.org/10.1111/anae.14144
DO  - doi:10.1111/anae.14144
SP  - 85
EP  - 94
KW  - acute kidney injury (AKI)
KW  - risk factors
KW  - peri-operative management
KW  - nephrotoxins
PY  - 2018
AB  - Summary Peri-operative acute kidney injury is common, accounting for 30?40% of all in-hospital cases of acute kidney injury. It is associated with clinically significant morbidity and mortality even with what was hitherto regarded as relatively trivial increases in serum creatinine, and carries over a 12-fold relative risk of death following major abdominal surgery. Comorbid conditions such as diabetes, hypertension, liver disease and particularly pre-existing chronic kidney disease, as well as the type and urgency of surgery, are major risk factors for the development of postoperative acute kidney injury. As yet, there are no specific treatment options for the injured kidney, although there are several modifiable risk factors of which the anaesthetist should be aware. As well as the avoidance of potential nephrotoxins and appropriate volume balance, optimal anaesthetic management should aim to reduce the risk of postoperative renal complications. This may include careful ventilatory management and blood pressure control, as well as appropriate analgesic strategies. The choice of anaesthetic agent may also influence renal outcomes. Rather than concentrate on the classical management of acute kidney injury, this review focuses on the potential development of acute kidney injury peri-operatively, and the means by which this may be ameliorated.
ER  - 

TY  - JOUR
TI  - Abstracts for the Annual Scientific Meeting of the Thoracic Society of Australia and New Zealand, 26 February – 3 March 1999, Canberra, Australia
JO  - Respirology
VL  - 4
IS  - S1
SN  - 9780470066386
UR  - https://doi.org/10.1111/resp.1999.4.s1.a1
DO  - doi:10.1111/resp.1999.4.s1.a1
SP  - A1
EP  - A65
PY  - 1999
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Nephrology
JA  - Nephrology
VL  - 18
IS  - S1
SN  - 9780470066386
UR  - https://doi.org/10.1111/nep.12121
DO  - doi:10.1111/nep.12121
SP  - 15
EP  - 76
PY  - 2013
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - American Journal of Transplantation
JA  - Am J Transplant
VL  - 17
IS  - S2
SN  - 9780470066386
UR  - https://doi.org/10.1111/ajt.14155
DO  - doi:10.1111/ajt.14155
SP  - 11
EP  - 92
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Catheterization and Cardiovascular Interventions
JA  - Cathet. Cardiovasc. Intervent.
VL  - 69
IS  - 6
SN  - 9780470066386
UR  - https://doi.org/10.1002/ccd.21200
DO  - doi:10.1002/ccd.21200
SP  - S1
EP  - S96
PY  - 2007
ER  - 

TY  - JOUR
TI  - Posters
JO  - Transplant International
JA  - Transpl Int
VL  - 26
IS  - s2
SN  - 9780470066386
UR  - https://doi.org/10.1111/tri.12214
DO  - doi:10.1111/tri.12214
SP  - 185
EP  - 339
PY  - 2013
ER  - 
